Sagar Lonial

Jan 20, 2025 | cancernetwork.com | Sagar Lonial |Ajay K. Nooka |Nisha Joseph |Jonathan Kaufman

January 20, 2025By Panelists discuss successful collaborations between academic centers and community practices in the context of (chimeric antigen receptor (CAR) T-cell therapy for multiple myeloma, key lessons learned in integrating CAR T therapy into the treatment landscape, and future plans for expanding CAR T therapy’s role in earlier lines of multiple myeloma treatment.

Jan 20, 2025 | cancernetwork.com | Sagar Lonial |Ajay K. Nooka |Nisha Joseph |Jonathan Kaufman

January 20, 2025By Panelists discuss a clinical scenario involving a 56-year-old male man with myeloma and del 17p deletion, treated with RVD induction, auto transplant, and lenalidomide maintenance, who relapsed after 2 years and is now referred to discuss chimeric antigen receptor (CAR) CAR-T versus vs standard therapy, sharing key takeaways and pearls from the case.

Jan 20, 2025 | cancernetwork.com | Sagar Lonial |Ajay K. Nooka |Nisha Joseph |Jonathan Kaufman

January 20, 2025By Panelists discuss their institution’s approach to co-management and co-monitoring of (chimeric antigen receptor (CAR) -T patients, strategies to facilitate seamless transitions of care between academic centers and community practices, common challenges in the CAR -T referral process and solutions, and advice for community physicians on the timing and preparation for patient referrals.

Jan 10, 2025 | cancernetwork.com | Sagar Lonial |Ajay K. Nooka |Nisha Joseph |Jonathan Kaufman

January 10, 2025 By Panelists discuss which patients are considered for CAR-T therapy in second-line treatment for relapsed/refractory multiple myeloma (R/R MM) (cilta-cel vs ide-cel), describe the specific criteria and institutional guidelines used to determine patient eligibility, and explore how non-medical factors like such as location and financial considerations impact patient selection, while also outlining the typical CAR-T referral process from community physician outreach to patient...

Jan 10, 2025 | cancernetwork.com | Sagar Lonial |Ajay K. Nooka |Nisha Joseph |Jonathan Kaufman

January 10, 2025By Panelists explain how CAR-T cell therapy works and describe the treatment process, discussing whether CAR -T is considered a complex procedure at their institution or if the logistics have been streamlined into clinical workflows, and they also detail their institution's approach to bridging therapy for patients awaiting CAR-T manufacturing and infusion, including whether patients are managed in-house or sent back to community centers.